Sinonasal undifferentiated carcinoma (SNUC) is an uncommon aggressive tumor. Locally advanced disease is usually diagnosed at presentation. Multidisciplinary approach is essential and aims to ensure optimal trimodal strategy. Induction chemotherapy is preferred in order to select patients who will benefit from chemoradiotherapy or surgery. Immunotherapy is not indicated in patients with recurrent SNUC. We describe an impressive response in a young man previously treated with radiotherapy and chemotherapy and demolitive surgery who had metastatic bone and lung disease. We also report data on PD-L1, next-generation sequencing, and neutrophil/platelets ratio.
López-HernándezAVivancoBFranchiA, et al. Genetic profiling of poorly differentiated sinonasal tumours. Sci Rep2018; 8: 3998.
3.
BellDBellAFerrarottoR, et al. High-grade sinonasal carcinomas and surveillance of differential expression in immune related transcriptome. Ann Diagn Pathol2020; 49: 151622.
4.
XuYZouRWangJ, et al. The role of the cancer testis antigen PRAME in tumorigenesis and immunotherapy in human cancer. Cell Prolif2020; 53: e12770.
5.
DilhuydyJMLagardePAllalAS, et al. Ethmoidal cancers: a retrospective study of 22 cases. Int J Radiat Oncol Biol Phys1993; 25: 113–116.
6.
GamezMELalDHalyardMY, et al. Outcomes and patterns of failure for sinonasal undifferentiated carcinoma (SNUC): the Mayo Clinic experience. Head Neck2017; 39: 1819–1824.
7.
MorandGBAndereggNVitalD, et al. Outcome by treatment modality in sinonasal undifferentiated carcinoma (SNUC): a case-series, systematic review and meta-analysis. Oral Oncol2017; 75: 28–34.
8.
AmitMAbdelmeguidASWatcherpornT, et al. induction chemotherapy response as a guide for treatment optimization in sinonasal undifferentiated carcinoma. J Clin Oncol2019; 37: 504–512.
9.
XuCCDziegielewskiPTMcGawWT, et al. Sinonasal undifferentiated carcinoma (SNUC): the Alberta experience and literature review. J Otolaryngol Head Neck Surg2013; 42: 2.
10.
García-MarínRRedaSRiobelloC, et al. CD8+ Tumour-infiltrating lymphocytes and tumour microenvironment immune types as biomarkers for immunotherapy in sinonasal intestinal-type adenocarcinoma. Vaccines2020; 8: 202.
11.
YaziciGGulluICengizM, et al. The synergistic effect of immune checkpoint blockade and radiotherapy in recurrent/metastatic sinonasal cancer. Cureus2018; 10: e3519.
